When Jacob Becraft addressed a bustling party of a hundred-plus employees, friends, and investors at his startup’s lab last month, he credited messenger RNA for bringing everyone back together in one room.
His remarks carried a double meaning. Yes, the mRNA vaccines had allowed the large group to gather in person — not a mask in sight. But Becraft’s Strand Therapeutics is also one of several Boston-area startups buoyed by the success of the COVID-19 shots and hoping to expand the reach of mRNA medicines into cancer and other diseases.
That night, Strand was celebrating the opening of its new headquarters in Fenway — a neighborhood known for baseball, not biotech. As the packed house chattered over cocktails and a musician playing acoustic covers, Becraft, the startup’s cofounder and chief executive, was quietly reveling in another milestone.
Create a display name to comment
This name will appear with your comment
